Crizotinib-d5

• CAT Number: R054513
• CAS Number: 1395950-48-7
• Molecular Formula: C21H22Cl2FN5O
• Molecular Weight: 450.34
• Purity: ≥95%
• Synonyms: 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl-d4)-1H-pyrazol-4-yl]-2-pyridinamine-d5; (R)-3-[1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl-d4)-1H-pyrazol-4-yl]pyridin-2-ylamine-d5; PF 02341066-d5; PF 2341066-d5; [3-
• Storage: -20°C

Crizotinib-d5（Cat No.:R054513） is a deuterated form of Crizotinib, where five hydrogen atoms are replaced with deuterium. This isotopic enhancement boosts the stability and precision of the molecule, especially valuable in pharmacokinetic and metabolic research. Crizotinib is an anticancer medication used primarily to treat non-small cell lung cancer, targeting and inhibiting the activity of ALK (anaplastic lymphoma kinase) and ROS1 proteins which are involved in the growth of cancer cells. Crizotinib-d5 provides more accurate insights into the drug’s behavior, distribution, and breakdown in the body, facilitating the optimization of therapeutic strategies and monitoring of side effects.